Daily Newsletter

11 September 2023

Daily Newsletter

11 September 2023

Grit Biotechnology secures funds for development of pipeline programmes

The funds will be used to progress the Phase II trial of GT101 and next-gen gene-edited tumour-infiltrating lymphocyte products.

Vishnu Priyan September 11 2023

Cell therapy company Grit Biotechnology has secured more than $60m (436.72m yuan) in a Series B funding round to support the development of its pipeline programmes.

China International Capital Corporation led the financing round, which saw investments from Liando Group, Qianhai Ark, Yuanhe Capital and HeFangTian Venture Partnership.

Grit's existing investors, namely Sherpa Healthcare Partners, Matrix Partners China and Decheng Capital, also took part in the financing round.

Grit plans to utilise the investment proceeds to support the development of its tumour-infiltrating lymphocyte (TIL) pipeline.

These funds will also be used for the Phase II clinical trial of TIL therapy, GT101, and progress next-gen gene-edited TIL products. 

GT101 is set to enter the Phase II trial by year-end.

Grit Biotechnology was established in 2019 and is focused on offering transformative therapies for cancer. 

The company uses four technology platforms for developing gene-edited TIL products: StemTexp, StaViral, KOReTIL and genome-wide CRISPR/Cas9 screening platform ImmuT Finder. 

Apart from GT101, the company is developing GT201, a genetically engineered TIL product, and a next-gen TIL product, GT316.  

GT201 has received new drug application clearance from the China Food and Drug Administration and is currently being evaluated in Phase I trials while GT316 is in investigator-initiated trials in the region.

Grit has a 10,000m² GMP-level cell therapy production facility in Suzhou with a workforce of more than 100 specialists.

Significant opportunities and risks for disease-modifying therapies (DMTs) entering the PD market

As PD therapy currently centers on symptomatic treatment, the need for DMTs is one of the greatest unmet needs. Several companies within the late-stage PD pipeline are developing drugs that target PD via novel MOAs. KOLs remain hopeful that these companies will uncover a class of drugs that works effectively to slow or modify the disease course. Targeting α-synuclein and other neurotoxic proteins is a key strategy in the late-stage pipeline for DMTs.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close